Luis Chu
Impact in
- Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Cancer Research top 5%
- Breast Cancer Treatment Studies
Papers in
-
- Renal cell carcinoma treatment 3
- Prostate Cancer Treatment and Research 2
- Oncology 5
- Cancer Treatment and Pharmacology 3
- Colorectal Cancer Treatments and Studies 3
- Co-authors
- Séamus O’Reilly (2 shared papers)Nicholas J. Petrelli (2 shared papers)Louis Fehrenbacher (2 shared papers)Linda H. Colangelo (2 shared papers)James N. Atkins (2 shared papers)Catherine A. Azar (2 shared papers)Norman Wolmark (3 shared papers)Thomas E. Seay (2 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)Blood (2 papers)Cancer (2 papers)Clinical Cancer Research (1 paper)Oncology (1 paper)
- Partner nations
- United StatesCanadaIreland
In The Last Decade
Luis Chu
17 papers receiving 1.5k citations
Luis Chu's Hit Papers
Peers
Comparison fields: 5 of 75
- Oncology 657
- Cancer Research 322
- Pulmonary and Respiratory Medicine 475
- Pathology and Forensic Medicine 236
- Hepatology 86
Countries citing papers authored by Luis Chu
This map shows the geographic impact of Luis Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Chu more than expected).
Fields of papers citing papers by Luis Chu
This network shows the impact of papers produced by Luis Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Chu. The network helps show where Luis Chu may publish in the future.
Co-authors
The 25 scholars most cited alongside Luis Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 Hit paper breakdown → | 2010 | 430 |
| 2 | 2009 | 210 | |
| 3 | 2010 | 207 | |
| 4 | 1998 | 201 | |
| 5 | 2011 | 192 | |
| 6 | 2008 | 93 | |
| 7 | 2005 | 44 | |
| 8 | 2010 | 35 | |
| 9 | Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. | 1995 | 28 |
| 10 | 2010 | 20 | |
| 11 | 2007 | 19 | |
| 12 | 1989 | 15 | |
| 13 | Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. | 1996 | 12 |
| 14 | 2012 | 7 | |
| 15 | 2013 | 4 | |
| 16 | 2017 | 1 | |
| 17 | 2011 | 1 | |
| 18 | 2015 | 0 |
About Luis Chu
Luis Chu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hematology, Cancer Research and Infectious Diseases, having authored 18 papers that have together received 1.5k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (3 papers), Multiple Myeloma Research and Treatments (3 papers), Cancer Treatment and Pharmacology (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Prostate Cancer Treatment and Research (2 papers), Cancer therapeutics and mechanisms (2 papers), HIV/AIDS drug development and treatment (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Oncology (657 citations), Cancer Research (322 citations), Pulmonary and Respiratory Medicine (475 citations), Pathology and Forensic Medicine (236 citations) and Hepatology (86 citations). Luis Chu has collaborated with scholars based in United States, Canada and Ireland. Frequent co-authors include Séamus O’Reilly, Nicholas J. Petrelli, Louis Fehrenbacher, Linda H. Colangelo, James N. Atkins, Catherine A. Azar, Norman Wolmark, Thomas E. Seay, Saima Sharif and Samia Lopa. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer, Clinical Cancer Research and Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.